tert-butyl 4-(3-methylbenzyl)piperazine-1-carboxylate | 203047-32-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-(3-methylbenzyl)piperazine-1-carboxylate
• 英文别名: N-tert-Butoxycarbonyl 1-(3-Methylbenzyl)piperazine；tert-butyl 4-[(3-methylphenyl)methyl]piperazine-1-carboxylate
• CAS: 203047-32-9
• 化学式: C₁₇H₂₆N₂O₂
• 分子量: 290.406
• InChiKey: WMBMUICSIFOYRW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(3-methylbenzyl)piperazine-1-carboxylate 在 三氟乙酸 作用下， 以 甲苯 为溶剂， 反应 1.2h， 生成 1-(3-甲基苯甲基)哌嗪
  参考文献：
  名称：

  体内具有强大抗血栓形成活性的新型蛋白酶激活受体1拮抗剂的发现

  摘要：

  蛋白酶激活受体（PARs）或凝血酶受体构成一类G蛋白偶联受体（GPCR），与许多生理机制的激活有关。因此，凝血酶通过这些受体的活化来活化许多细胞类型，例如血管平滑肌细胞，白细胞，内皮细胞和血小板。在人类中，凝血酶诱导的血小板凝集是由一种称为PAR1的亚型介导的。本文介绍了这些受体的新拮抗剂的发现，更具体地说，发现了两种化合物：2- [5-氧代-5-（4-吡啶-2-基哌嗪-1-基）戊-1,3-二烯基]苄腈36（ F 16618）和3-（2-氯苯基）-1- [4-（4-氟苄基）哌嗪-1-基]丙烯酮39（F 16357），是在优化后获得的。在静脉内或口服给药后，在大鼠的动静脉分流模型中，这两种化合物均能够抑制SFLLR诱导的人血小板聚集并显示抗血栓形成活性。此外，这些化合物没有其他类型的抗血小板药物经常观察到的出血副作用，这构成了这类新型抗血栓药的有希望的优势。

  DOI：

  10.1021/jm900553j
• 作为产物：
  描述：

  N-Boc-哌嗪 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 tert-butyl 4-(3-methylbenzyl)piperazine-1-carboxylate
  参考文献：
  名称：

  Synthesis and receptor binding studies of novel 4,4-disubstituted arylalkyl/arylalkylsulfonyl piperazine and piperidine-based derivatives as a new class of σ1 ligands

  摘要：

  This study presents the synthesis and biological evaluation of a new series of arylalkyliary/alkylsulfonyl piperazine and piperidine-based derivatives as sigma receptor ligands. It was found that a number of halogen substituted sulfonamides display relatively high and low affinities to sigma(1) and sigma(2) receptors, respectively. The sigma(1) affinities and subtype selectivities of four piperidine derivatives were also found to be generally comparable to those of piperazine analogues. Compared to sigma(1)-Rs compounds with n = 0 and 2, those with n = 1 proved to have optimal length of carbon chain by exhibiting higher affinities.Within this series, the 4-benzyl-1-(3-iodobenzylsulfonyl)piperidine sigma ligand was identified with 96-fold sigma(1)/sigma(2) selectivity ratio (K-i sigma(i) = 0.96 +/- 0.05 nM and K-i sigma(2) = 91.8 +/- 8.1 nM). (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.04.013

文献信息

• Discovery of Novel Protease Activated Receptors 1 Antagonists with Potent Antithrombotic Activity in Vivo
  作者：Michel Perez、Marie Lamothe、Catherine Maraval、Etienne Mirabel、Chantal Loubat、Bruno Planty、Clemens Horn、Julien Michaux、Sebastien Marrot、Robert Letienne、Christophe Pignier、Arnaud Bocquet、Florence Nadal-Wollbold、Didier Cussac、Luc de Vries、Bruno Le Grand

  DOI：10.1021/jm900553j

  日期：2009.10.8

  Protease activated receptors (PARs) or thrombin receptors constitute a class of G-protein-coupled receptors (GPCRs) implicated in the activation of many physiological mechanisms. Thus, thrombin activates many cell types such as vascular smooth muscle cells, leukocytes, endothelial cells, and platelets via activation of these receptors. In humans, thrombin-induced platelet aggregation is mediated by

  蛋白酶激活受体（PARs）或凝血酶受体构成一类G蛋白偶联受体（GPCR），与许多生理机制的激活有关。因此，凝血酶通过这些受体的活化来活化许多细胞类型，例如血管平滑肌细胞，白细胞，内皮细胞和血小板。在人类中，凝血酶诱导的血小板凝集是由一种称为PAR1的亚型介导的。本文介绍了这些受体的新拮抗剂的发现，更具体地说，发现了两种化合物：2- [5-氧代-5-（4-吡啶-2-基哌嗪-1-基）戊-1,3-二烯基]苄腈36（ F 16618）和3-（2-氯苯基）-1- [4-（4-氟苄基）哌嗪-1-基]丙烯酮39（F 16357），是在优化后获得的。在静脉内或口服给药后，在大鼠的动静脉分流模型中，这两种化合物均能够抑制SFLLR诱导的人血小板聚集并显示抗血栓形成活性。此外，这些化合物没有其他类型的抗血小板药物经常观察到的出血副作用，这构成了这类新型抗血栓药的有希望的优势。
• US5817489A
  申请人：——

  公开号：US5817489A

  公开（公告）日：1998-10-06
• Synthesis and receptor binding studies of novel 4,4-disubstituted arylalkyl/arylalkylsulfonyl piperazine and piperidine-based derivatives as a new class of σ1 ligands
  作者：Masoud Sadeghzadeh、Shahab Sheibani、Mehdi Ghandi、Fariba Johari Daha、Massoud Amanlou、Mohammad Arjmand、Abolfazl Hasani Bozcheloie

  DOI：10.1016/j.ejmech.2013.04.013

  日期：2013.6

  This study presents the synthesis and biological evaluation of a new series of arylalkyliary/alkylsulfonyl piperazine and piperidine-based derivatives as sigma receptor ligands. It was found that a number of halogen substituted sulfonamides display relatively high and low affinities to sigma(1) and sigma(2) receptors, respectively. The sigma(1) affinities and subtype selectivities of four piperidine derivatives were also found to be generally comparable to those of piperazine analogues. Compared to sigma(1)-Rs compounds with n = 0 and 2, those with n = 1 proved to have optimal length of carbon chain by exhibiting higher affinities.Within this series, the 4-benzyl-1-(3-iodobenzylsulfonyl)piperidine sigma ligand was identified with 96-fold sigma(1)/sigma(2) selectivity ratio (K-i sigma(i) = 0.96 +/- 0.05 nM and K-i sigma(2) = 91.8 +/- 8.1 nM). (C) 2013 Elsevier Masson SAS. All rights reserved.
• Design, synthesis, and evaluation of formylpiperazine analogs of Ferrostatin-1 as novel improved ferroptosis inhibitors
  作者：Hua-Long Ji、Yi-Fan Zhang、Nai-Yu Zhang、Kai-Ming Wang、Ning Meng、Juan Zhang、Cheng-Shi Jiang

  DOI：10.1016/j.bmc.2024.117716

  日期：2024.5

  study, a series of new formylpiperazine-derived ferroptosis inhibitors were designed and synthesized based on the structure of a known ferroptosis inhibitor, ferrostatin-1 (Fer-1). The anti-ferroptosis activity of these synthetic compounds in human umbilical vein endothelial cells (HUVECs) induced by Erastin was evaluated. It was found that some of the new compounds, especially compound , showed potent

  本研究基于已知的铁死亡抑制剂铁他汀-1（Fer-1）的结构，设计并合成了一系列新型甲酰基哌嗪衍生的铁死亡抑制剂。评估了这些合成化合物在 Erastin 诱导的人脐静脉内皮细胞 (HUVEC) 中的抗铁死亡活性。研究发现，一些新化合物，特别是化合物 ，表现出有效的抗铁死亡活性，其能够恢复细胞活力、减少铁积累、清除活性氧、维持线粒体膜电位、增加 GSH 水平、降低 LPO和 MDA 含量，并上调 GPX4 表达。此外，该化合物表现出比Fer-1更优异的微粒体稳定性。目前的结果表明，该化合物是开发治疗血管疾病的新型铁死亡抑制剂的有前途的先导化合物。